SWOG clinical trial number
S0437
Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed with Prostate Cancer
Closed
Phase
Accrual
53%
Abbreviated Title
PCPT Long Term Follow Up
Activated
09/01/2005
Closed
03/01/2009
Participants
PCPT Institutions with Participants who were Diagnosed with Prostate Cancer on or Before 12/31/03
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Participants randomized in the Prostate Cancer Prevention Trial (PCPT, SWOG-9217) who were diagnosed with prostate cancer on or before December 31, 2003
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase